KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $182.0 million.

  • Twist Bioscience's Total Liabilities rose 1922.9% to $182.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $182.0 million, marking a year-over-year increase of 1922.9%. This contributed to the annual value of $168.9 million for FY2025, which is 1925.31% up from last year.
  • As of Q4 2025, Twist Bioscience's Total Liabilities stood at $182.0 million, which was up 1922.9% from $168.9 million recorded in Q3 2025.
  • Twist Bioscience's 5-year Total Liabilities high stood at $182.0 million for Q4 2025, and its period low was $6.0 million during Q4 2021.
  • For the 5-year period, Twist Bioscience's Total Liabilities averaged around $140.6 million, with its median value being $152.7 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 9026.26% in 2021, then soared by 262741.67% in 2022.
  • Twist Bioscience's Total Liabilities (Quarter) stood at $6.0 million in 2021, then surged by 2627.42% to $163.6 million in 2022, then fell by 12.75% to $142.8 million in 2023, then increased by 6.91% to $152.6 million in 2024, then increased by 19.23% to $182.0 million in 2025.
  • Its last three reported values are $182.0 million in Q4 2025, $168.9 million for Q3 2025, and $165.4 million during Q2 2025.